soul trial oral semaglutide cardiovascular outcomes results 2024 Effect of on in Type 2 Diabetes by Extent of Vascular Disease Oral semaglutide found to lower

4 In 2017, cardiovascular outcomes data from the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial demonstrated that inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) with evolocumab on a background of statin therapy was efficacious in patients with stable atherosclerotic cardiovascular disease (ASCVD) and additional high-risk features

the GLP-1 agonist class transition from injectable specialty drugs to mainstream Type-2 first-line therapy, compressing treatment timelines

Whether youre curious about a treatment, booking your first consultation, or continuing your care, our team is here to guide and support you every step of the way.

An alloy is a solid or liquid solution that consists of one or more elements in a metallic matrix